ACET ADICET BIO INC US FDA Inspections 8-K Filing 2024 - FDA Clearance Adicet Bio, Inc. announced that the FDA cleared its IND amendment to evaluate ADI-001 in patients with idiopathic inflammatory myopathy and stiff person syndrome, with plans to start enrollment in early 2025 as part of a Phase 1 trial involving multiple autoimmune diseases.Get access to all SEC 8-K filings of the ADICET BIO INC